Slide 1: Innovate the way we see life
Innovate the way we see life Investor Relations 2025 Tomocube, Inc.
Slide 2: Disclaimer
Disclaimer This material has been prepared by Tomocube, Inc. (“the Company”) for informational purposes in investor presentations. The forward-looking statements contained herein have not been independently verified. These statements relate to future events and include the Company’s expectations reg
Slide 3: Table of contents
Table of contents Prologue Chapter 1. Why Holotomography(HT) Chapter 2. Expanding the applications of HT Chapter 3. Investment Highlights Appendix
Slide 4: Paradigm Shift in Cell Analysis
Prologue Tomocube, Inc. I 4 Paradigm Shift in Cell Analysis Growth drivers: 3D Biology & Regenerative Medicine NEW era Organoids 3D Biology, Regenerative Medicine Cell Therapies organoids and cell therapies can be utilized in drug Complex 3D organ-mimicking structures development, companion Disease
Slide 5: Unmet Needs Addressed by Holotomography
Prologue Tomocube, Inc. I 5 Unmet Needs Addressed by Holotomography Fulfilling Unmet Needs in the Advanced Biomedical Sector Conventional HT(“Holotomography”) Transformative Effects Unsuitable for therapeutic Applicable for therapeutic Fluorescence-based purposes imaging application Label-free cell
Slide 6: Setting new standards in cell analysis through Holotomography
Prologue Tomocube, Inc. I 6 Setting new standards in cell analysis through Holotomography Just as CT Transformed Diagnosis, HT is Poised to Transform Bioanalysis CT Similarity HT (Computed tomography) (Holotomography) X-ray Light source Laser, LED Cells, Human Specimen tissues Cell X-ray Refractive
Slide 7: Leading Advanced Bio/Medical Industry
Prologue Tomocube, Inc. I 7 Leading Advanced Bio/Medical Industry Pioneering Holotomography: From Innovation to Global Commercialization Paradigm Shift in Bioimaging 3D Biology & Regenerative Medicine The Evolution of Cell Imaging in the Era of Bio-Analysis Transformation 3D Cell Structure Measureme
Slide 8: Cancer cell
@ Cancer cell Tomocube Label-free 3D tive vat imagine, . Cellular Responses and Recovery from High Leliél.af Redtive Oxygen Species (ROS) * Cell line: Hep3B J * Microscope: HT-X1 VES * Observation duration: 4.5 hr + Time interval: 20 sec * Chip: ibidi u-Slide | Luer + Flow rate: 0.23 yL/min 20 ym
Slide 9: Organoid
Cancer cell ©: Organoid Tomocube So Unveiling the unseen: 3D Organoid visualization Cell division #(116/361) 00:57:30
Slide 10: Why Holotomography (HT)
Chapter 1. Why Holotomography (HT) 01. Key Advantages of Holotomography 02. HT Platform (1) Hardware (2) Software (3) AI 03. Distinct Competitive Advantages (1) Holotomography Comparison (2) Cell Analysis Technology Comparison 04. Externally Validated Technology
Slide 11: 01. Key Advantages of Holotomography
Chapter 1. Why Holotomography(HT) Tomocube, Inc. I 11 01. Key Advantages of Holotomography Establishing a Competitive Business Model Through Proprietary Hardware, Software, and AI solutions Holotomography Platform Hardware Software AI 00:00 h 19:00 h Lipid droplet Volume: 40.265 (µ㎥) Volume: 345.305
Slide 12: 02. HT Platform (1) Hardware
Chapter 1. Why Holotomography(HT) Tomocube, Inc. I 12 02. HT Platform (1) Hardware Establishing a Standard Protocol for 3D Label-Free Imaging Unmet Needs Hardware Competencies Accurate 3D Cellular Analysis of Thick Limitations of Enables Observation of Cells in Their Native State Tissues, Organoids,
Slide 13: 02. HT Platform (2) Software
Chapter 1. Why Holotomography(HT) Tomocube, Inc. I 13 02. HT Platform (2) Software From Custom Solutions to an Integrated Analysis Platform Expanded application areas Software Competencies through AI model-based software 2022 2024 TomoAnalysis 1.0 TomoAnalysis 2.0 Demand-Based Solution Development 2
Slide 14: 02. HT Platform (3) AI
Chapter 1. Why Holotomography(HT) Tomocube, Inc. I 14 02. HT Platform (3) AI World-Leading AI-Powered Analysis Platform for HT Imaging and Biomarker Discovery 01 02 Quality Improvement via AI Automated Cell/Organelle Segmentation Maximizing HT imaging definition Automated quantitative analysis of &
Slide 15: 03. Distinct Competitive Advantages: Holotomography Comparison
Chapter 1. Why Holotomography(HT) Tomocube, Inc. I 15 03. Distinct Competitive Advantages: Holotomography Comparison Tomocube: Defining the History of Holotomography HT Technology Paradigm Shifts & Milestones 1st Generation 2nd Generation Future 1st Gen HT 1st Gen HT Category 2nd Gen HT (Tomocube) F
Slide 16: 03. Distinct Competitive Advantages: Cell Analysis Technology Comparison
Chapter 1. Why Holotomography(HT) Tomocube, Inc. I 16 03. Distinct Competitive Advantages: Cell Analysis Technology Comparison Setting the Benchmark in Cell Analysis: Tomocube vs. Competitors Necessary Specs Comparison with Other Optical Devices 2nd GEN HT 3D Multimodal Artificial Category Resolutio
Slide 17: 04. Externally Validated Technology with robust IP protection
Chapter 1. Why Holotomography(HT) Tomocube, Inc. I 17 04. Externally Validated Technology with robust IP protection 81 Granted and Pending Patents; Domestic & International Recognition • Research in HT precision Foundational research in label-free • Developed • Developed AI-based Initiated research
Slide 18: Expanding the applications of HT
Chapter 2. Expanding the applications of HT 01. Tomocube’s Target Market 02. Opportunity # 1 Organoids Opportunity # 2 In Vitro Fertilization Opportunity # 3 Cell Therapies Opportunity # 4 Drug Development Opportunity # 5 Non-Bio Industrial Applications
Slide 19: 01. Tomocube's Target Market
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 19 01. Tomocube’s Target Market 3D Biology & Regenerative Medicine Market Growth Market Size Projection 2027 Approx. 120 trillion KRW+ α Organoids In Vitro Fertilization (IVF) Cell Therapy High-Content Screening Organoid analysis in live c
Slide 20: 02. Expanding Applications of HT(1): Organoids
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 20 02. Expanding Applications of HT(1): Organoids* Organoids as a new model in Advanced Bioindustry Animal Testing Termination Organoid-based Alternative R&D using organioids bio/pharmaceutical USA(2022), EU(2025) paradigm shift Top 15 glo
Slide 21: 02. Expanding Applications of HT(1): Organoids
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 21 02. Expanding Applications of HT(1): Organoids Standardization of Organoid Analysis Using HT Collaboration with Global Top Pharmas Collaborating w/ US-KOR Gov’t Agencies Phenotypic Analysis of Organoid Cells Using AI-powered Holotomogra
Slide 22: 02. Expanding Applications of HT(2): IVF
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 22 02. Expanding Applications of HT(2): IVF 3D Label-Free HT Imaging and AI for Selecting High-Implantation Embryos Conventional Unmet Needs Synergies from strategic partnerships • Label-free imaging is essential for embryo selection proce
Slide 23: 02. Expanding Applications of HT(3): Cell Therapy
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 23 02. Expanding Applications of HT(3): Cell Therapy Transformative Solution for Quality Control in Cell Therapy Manufacturing HT powered analysis S/W allowing Non-invasive QC Process for Cell Therapy Improvements in cell therapeutics manu
Slide 24: 02. Expanding Applications of HT(4): Drug Development
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 24 02. Expanding Applications of HT(4): Drug Development Application of HT in Phenotypic Drug Discovery (PDD) Improving Phenotypic Drug Discovery with HT and AI Entering new PDD markets using AI TDD Target-Based Drug Discovery feature extr
Slide 25: 02. Expanding Applications of HT(5): Non-Bio Industrial Use
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 25 02. Expanding Applications of HT(5): Non-Bio Industrial Use Non-Destructive Testing: Key Challenges in Glass Substrate and TGV Manufacturing Non-invasive 3D Inspection of Laser modulation and internal crack testing Through Glass Via(TGV
Slide 26: 02. Expanding Applications of HT(5): Non-Bio Industrial Use
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 26 02. Expanding Applications of HT(5): Non-Bio Industrial Use High-Throughput Metrology: Key Challenges in Hybrid Bonding and CMP Process Control 3D analysis of Wafer (Hybrid Bonding) Post CMP Testing Improving advanced packaging by Hi-Re
Slide 27: 02. Expanding Applications of HT(5): Non-Bio Industrial Use
Chapter 2. Expanding the applications of HT Tomocube, Inc. I 27 02. Expanding Applications of HT(5): Non-Bio Industrial Use Continuous R&D enabling the expansions beyond semiconductor and display sectors New product launching 3D measurement modules & device Early Providing modules to machinery/devic
Slide 28: Investment Highlights
Chapter 3. Investment Highlights 01. Tomocube’s Key Success Factors 02. Proven Technology Excellence 03. Proven Commercial Viability 04. Global Expansion Strategy 05. Leading Localization in Bio Equipment Manufacturing 06. 1Q25 Financial Highlights
Slide 29: 01. Tomocube's Success Factors
Chapter 3. Investment Highlights Tomocube, Inc. I 29 01. Tomocube’s Success Factors Advanced Deep Tech Innovator in Bio Industry First Player Sufficient Capitals World’s First Commercialization of 2nd Gen Investment from Major Global Holotomography Companies and VCs Mkt. Cap. Tomocube 5 + yrs HT Com
Slide 30: 02. Proven Technological Excellence
Chapter 3. Investment Highlights Tomocube, Inc. I 30 02. Proven Technological Excellence Holotomography Recognition in Global Market Tomocube is leading global technology developments Major International Collaborations and Holotomography featured in top publications by industry Conferences Competiti
Slide 31: 03. Proven Commercial Viability
Chapter 3. Investment Highlights Tomocube, Inc. I 31 03. Proven Commercial Viability HT Expected to Show Explosive Growth as Best-in-Class Technology High satisfaction from customer base A Continuously Growing Vanderbilt HT-X1 Revenue Pipeline University Plus HT Demo provisions(cumulated) Unit: case
Slide 32: 04. Global Expansion Strategy
Chapter 3. Investment Highlights Tomocube, Inc. I 32 04. Global Expansion Strategy Expansion of Direct Sales & Distribution Networks Globally Global expansion Quality references Extensive B/D and marketing Tomocube Europe European subsidiary to be established in 2Q 2025 Tomocube USA D2C & 12 Distrib
Slide 33: 05. Leading Localization in Bio Equipment Manufacturing
Chapter 3. Investment Highlights Tomocube, Inc. I 33 05. Leading Localization in Bio Equipment Manufacturing Direct Beneficiary of Government’s Bio Equipment Localization Policy KR Government’s subsidy on 5% or less for cell analysis domestic device R&D equipment and other device dev. “20% or more t
Slide 34: 06. 1Q25 Financial Highlights
Chapter 3. Investment Highlights Tomocube, Inc. I 34 06. 1Q25 Financial Highlights Summary Income Statement 1Q Revenue Recorded at KRW 650 Million (YoY -46.0%, QoQ -35.0%): Revenue declined due to organizational restructuring and transition in distribution strategy. A significant portion of expected
Slide 35: 06. 1Q25 Financial Highlights
Chapter 3. Investment Highlights Tomocube, Inc. I 35 06. 1Q25 Financial Highlights Financial Statements Statement of Financial Position Unit : million KRW Income Statement Unit : million KRW Category 2022 2023 2024 1Q25 Category 2022 2023 2024 1Q25 Current Assets 22,126 15,952 40,062 36,407 Sales 1,
Slide 36: Appendix
Appendix 01. Board of Directors 02. Key Personnel
Slide 37: 01. Board of Directors
Appendix Tomocube, Inc. I 37 01. Board of Directors Independent, professional board with a focus on accountability YongKeun Park Chairman of the Board, CEO Sang-Il Park Outside Director Education Ph.D. in Health Science and Technology, Harvard-MIT Education Ph.D., Stanford University Career Co-found
Slide 38: 02. Senior Executives
Appendix Tomocube, Inc. I 38 02. Senior Executives More than 10 years of experienced management and development personnel in the relevant field YongKeun Park CEO Sung-Ho Ko COO Education Ph.D. in Health Science and Technology, Harvard-MIT Education M.S. in Industrial Engineering, KAIST Career Co-fou
Slide 39: Tomocube
4} Tomocube